<DOC>
	<DOCNO>NCT01493427</DOCNO>
	<brief_summary>The purpose study assess efficacy tolerability TRAVATAN® Solution without benzalkonium chloride ( BAK ) patient previously latanoprost 0.005 % bimatoprost 0.01 % ophthalmic solution monotherapy .</brief_summary>
	<brief_title>Efficacy Changing TRAVATAN® From Prior Therapy</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<criteria>Clinical diagnosis ocular hypertension openangle glaucoma least one eye . Be either latanoprost 0.005 % bimatoprost 0.01 % ophthalmic solution monotherapy ( include BAKcontaining generic ) least four week prior Screening visit . Would benefit switch TRAVATAN® Solution without BAK contain Polyquad® Preservative due tolerability issue , opinion investigator . IOP consider safe ( opinion investigator ) , eye , way assure clinical stability vision optic nerve throughout study period . Willing discontinue use ocular hypotensive medication prior receive study medication entire course study . Best correct Snellen visual acuity 6/60 ( 20/200 , 1.0 LogMAR ) good eye Other protocoldefined inclusion criterion may apply . Known medical history allergy , hypersensitivity , poor tolerance component preparation use study deem clinically significant opinion Principal Investigator . Any abnormality prevent reliable applanation tonometry either eye . Severe dry eye relate currently treat use punctal plug , punctal cautery , Restasis® , topical ocular corticosteroid . Any clinically significant , serious , severe medical condition . Intraocular conventional surgery laser surgery either eye less three month prior Screening Visit . Risk visual field visual acuity worsen consequence participation study , investigator 's best judgment . Progressive retinal optic nerve disease cause . Women pregnant , lactate . Women use reliable mean birth control . Use systemic medication know affect IOP stable course least 7 day prior Screening Visit . Any clinically significant , serious , severe medical condition . Participation investigational study within 30 day Screening Visit . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>OAG</keyword>
	<keyword>OHT</keyword>
</DOC>